Neuroradiological findings of bleomycin leakage in cystic craniopharyngioma. Report of three cases
- PMID: 17941498
- DOI: 10.3171/PED-07/10/318
Neuroradiological findings of bleomycin leakage in cystic craniopharyngioma. Report of three cases
Abstract
Intracystic bleomycin therapy has been proposed as a treatment for predominantly cystic craniopharyngioma. The risks of using this therapy, however, have not been clearly identified. The authors report on three children treated with intracystic bleomycin who developed initially mild symptoms during their course of therapy. They describe the neuroimaging findings from computed tomography (CT) scans and magnetic resonance (MR) images and the medical management of these three cases. Two patients in whom craniopharyngioma was recently diagnosed and one patient with recurrent craniopharyngioma were treated with a course of 3 mg of intracystic bleomycin three times a week for 5 weeks, followed by once every week for 10 weeks. All patients had a negative reservoir permeability test prior to beginning intracystic bleomycin therapy. Patients were asymptomatic or had mild symptoms at the time of neuroimaging. Magnetic resonance images revealed extensive vasogenic edema surrounding the cyst in all three patients, consistent with signs of bleomycin leakage. The edema occurred near the time of the 12th injection in two patients, and at the end of treatment in the remaining patient. Subsequently, two patients developed further symptoms suggestive of hypothalamic injury. These two patients received corticosteroids, leading to a rapid and sustained clinical improvement. Follow-up serial MR images showed a progressive regression of the surrounding edema. Neuroimaging documentation of bleomycin toxicity has been described mainly in adults experiencing severe toxicity. There was no correlation between clinical symptoms and the extent of edema in these three patients. An MR image provides a higher resolution than CT scans for evaluating the adjacent cerebral structures and is very sensitive in detecting early abnormalities, even in asymptomatic patients. Bleomycin therapy requires close clinical monitoring. Imaging evaluation should be performed using MR imaging during treatment to ensure the safety of the therapy. In the authors' experience, the toxicity to bleomycin was transient. Management of the toxicity using high-dose steroid administration appears to contribute to controlling the bleomycin-induced inflammatory process.
Similar articles
-
Delayed neurotoxic complication of intracavitary bleomycin therapy for craniopharyngioma in a child who had previously undergone radiosurgery. Case report.J Neurosurg. 2007 May;106(5 Suppl):391-3. doi: 10.3171/ped.2007.106.5.391. J Neurosurg. 2007. PMID: 17566208
-
Fatal toxic effect of bleomycin on brain tissue after intracystic chemotherapy for a craniopharyngioma: case report.Neurosurgery. 2000 Jan;46(1):213-6; discussion 216-7. Neurosurgery. 2000. PMID: 10626953
-
Vasculopathy after intracystic bleomycin administration for a recurrent cystic craniopharyngioma: case report.J Neurosurg Pediatr. 2012 Apr;9(4):394-9. doi: 10.3171/2012.1.PEDS11437. J Neurosurg Pediatr. 2012. PMID: 22462704
-
Intratumoural bleomycin as a treatment for recurrent cystic craniopharyngioma. Case report and review of the literature.Neurocirugia (Astur). 2002 Dec;13(6):479-85; discussion 485. doi: 10.1016/s1130-1473(02)70576-9. Neurocirugia (Astur). 2002. PMID: 12529778 Review.
-
Bleomycin treatment of brain tumors: an evaluation.Anticancer Drugs. 2009 Mar;20(3):157-64. doi: 10.1097/CAD.0b013e328325465e. Anticancer Drugs. 2009. PMID: 19396014 Review.
Cited by
-
Treatment of Cystic Craniopharyngiomas: An Update.Adv Tech Stand Neurosurg. 2022;45:139-176. doi: 10.1007/978-3-030-99166-1_4. Adv Tech Stand Neurosurg. 2022. PMID: 35976449
-
Old Tools in a New Era: The Continued Relevance of Chemotherapy in Pediatric Neuro-Oncology.Curr Oncol. 2025 Jul 20;32(7):410. doi: 10.3390/curroncol32070410. Curr Oncol. 2025. PMID: 40710220 Free PMC article. Review.
-
Phase II study of peginterferon alpha-2b for patients with unresectable or recurrent craniopharyngiomas: a Pediatric Brain Tumor Consortium report.Neuro Oncol. 2020 Nov 26;22(11):1696-1704. doi: 10.1093/neuonc/noaa119. Neuro Oncol. 2020. PMID: 32393959 Free PMC article. Clinical Trial.
-
Endoscopic Transcortical Transventricular Management of Cystic Craniopharyngioma: Outcome Analysis of 32 Cases at a Tertiary Care Center.Asian J Neurosurg. 2020 Dec 21;15(4):846-855. doi: 10.4103/ajns.AJNS_252_20. eCollection 2020 Oct-Dec. Asian J Neurosurg. 2020. PMID: 33708653 Free PMC article.
-
An update on multimodal management of craniopharyngioma in children.Front Oncol. 2023 May 5;13:1149428. doi: 10.3389/fonc.2023.1149428. eCollection 2023. Front Oncol. 2023. PMID: 37213301 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical